Beskrivning
| Land | Norge |
|---|---|
| Lista | OAX Equities |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2022-02-21 07:30:13
Mandatory disclosure pursuant to section 4-2 of the Norwegian Securities Trading
Act by TopRidge Pharma (Ireland) Limited ("TopRidge Pharma").
Reference is made to the previous stock exchange announcements from Observe
Medical ASA (the "Company") announcing a fully underwritten rights issue of
25,714,286 new shares in the Company, raising gross proceeds of approximately
NOK 180 million (the "Rights Issue").
In the Rights Issue, each existing shareholder of the Company as of 4 February
2022 (and being registered as such in Euronext Securities Oslo, the Norwegian
Central Securities Depository (the "VPS") as at the expiry of 8 February 2022)
were granted 1.311588 subscription rights for each share registered as held by
the shareholder.
Each subscription right gives the right to subscribe for one new share in the
Company in the Rights Issue. The subscription period commenced on 9 February
2022 and expires on 23 February 2022 at 16:30 CET. On 9 February 2022, TopRidge
Pharma received 1,859,204 subscription rights in the Rights Issue.
Following the completion of the Rights Issue, the share capital of the Company
will be NOK 11,783,133.18 divided into 45,319,743 shares.
The calculations below are based on the new share capital and number of shares
in the Company following the completion of the Rights Issue.
During the subscription period, TopRidge Pharma has sold all of its 1,859,204
subscription rights in the Rights Issue.
As of today, on 21 February 2022, TopRidge Pharma holds 1,417,522 shares and
voting rights in the Company, corresponding to 7.23% of the shares and voting
rights in the Company prior to the completion of the Rights Issue.
Following completion of the Rights Issue, TopRidge Pharma's aggregate holding of
shares and voting rights in the Company will be reduced to 3.13% of the total
number of shares and voting rights in the Company, and TopRidge Pharma is
thereby crossing the 5% threshold with regards to shares and voting rights in
the Company.